University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
Welcome,         Profile    Billing    Logout  
 128 Trials 
79 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Machtay, Mitchell
GRECO-2, NCT04698915: Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

Terminated
2
177
Europe, Canada, US
Drug GC4711, Placebo
Galera Therapeutics, Inc.
SBRT, Borderline Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer
11/23
11/23
Sloan, Andrew E
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
More
Recruiting
3
350
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
TVI-AST-008, NCT05685004: Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

Recruiting
2/3
120
US
TVI-Brain-1, Standard of Care, Radiotherapy, Temozolomide, Chemotherapy
TVAX Biomedical
Glioblastoma Multiforme of Brain
12/26
03/27
ImmuneSense, NCT04485949: A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma

Active, not recruiting
2
93
US
IGV-001 Cell Immunotherapy, Placebo, Standard of Care (SOC): Radiation Therapy, SOC: Temozolomide
Imvax
Glioblastoma
01/25
07/27
Krishnamurthi, Smitha
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
C-800-25, NCT05608044: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Active, not recruiting
2
234
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care
Agenus Inc.
Metastatic Colorectal Cancer
02/25
07/25
NCT05221320: Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

Terminated
2
47
US
Ulixertinib, BVD-523, BVD523, Hydroxychloroquine
BioMed Valley Discoveries, Inc
Tumor, Solid, Gastrointestinal Cancer
05/24
07/24
Jones, Robert
DETERMINE, NCT05768178: Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Recruiting
2/3
30
Europe
Vemurafenib, Zelboraf, Cobimetinib, Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms, Colorectal Neoplasms, Laryngeal Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioma, Multiple Myeloma, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic
10/29
10/29
CRUKD/21/004, NCT05722886: DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Recruiting
2/3
825
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Entrectinib, Rozlytrek, Trastuzumab in combination with pertuzumab, Herceptin in combination with Perjeta, Vemurafenib in combination with cobimetinib, Zelboraf in combination with Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy
10/29
10/29
DETERMINE, NCT05786716: Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations

Recruiting
2/3
30
Europe
Trastuzumab, Herceptin, Pertuzumab, Perjeta
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms, Salivary Gland Neoplasm, Lung Neoplasm, Pancreatic Neoplasm, Ovarian Neoplasms, Prostatic Neoplasm, Skin Neoplasm
10/29
10/29
DETERMINE, NCT05770102: Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Recruiting
2/3
30
Europe
Atezolizumab, Tecentriq
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Colorectal Neoplasms, Endometrial Neoplasms, Melanoma
10/29
10/29
DETERMINE, NCT05770037: Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers

Recruiting
2/3
30
Europe
Alectinib, Alecensa
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Anaplastic Large Cell Lymphoma, Lymphoma, Renal Cell Carcinoma, Neuroblastoma
10/29
10/29
DETERMINE, NCT05770544: Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.

Recruiting
2/3
30
Europe
Entrectinib, Rozlytrek
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Brain Neoplasms, Melanoma, Glioma
10/29
10/29
KEYNOTE-D78, NCT04879329: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Recruiting
2
372
Europe, Canada, Japan, US, RoW
disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Urothelial Carcinoma
11/26
05/28
FAKTION, NCT01992952: Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer

Checkmark From P1b/2 FAKTION trial for advanced ER+/HER2- breast cancer at ASCO 2019 [screenshot]
Jun 2019 - Jun 2019: From P1b/2 FAKTION trial for advanced ER+/HER2- breast cancer at ASCO 2019 [screenshot]
Active, not recruiting
1b/2
149
Europe
AZD5363, Placebo, Fulvestrant
Velindre NHS Trust, AstraZeneca, Cenduit LLC, Covance, Cardiff and Vale University Health Board
Estrogen Receptor Positive Breast Cancer
03/19
12/23
NCT04630262: ATTUNE Cementless FB Tibial Base Clinical Study

Terminated
N/A
80
US
ATTUNE Cementless CR Fixed Bearing, ATTUNE Cementless PS Fixed Bearing
DePuy Orthopaedics
Osteoarthritis of the Knee
03/23
03/23
WAVE, NCT04540302: The Merit WRAPSODY AV Access Efficacy Study

Active, not recruiting
N/A
357
Europe, Canada, US, RoW
Merit WRAPSODY Endovascular Stent Graft, PTA
Merit Medical Systems, Inc.
Venous Stenosis, Venous Occlusion
02/24
01/26
Mossie-GO, NCT06232954: Evaluation of the Protective Efficacy of a Spatial Repellent to Reduce Malaria Prevalence in Uganda

Recruiting
N/A
5600
RoW
Mossie-Go containing treated transfluthrin disc, Mossie-Go containing untreated blank disc
Africa Power Limited, Malaria Consortium, ARCTECH INNOVATION LIMITED
Malaria, Mosquito-Borne Disease
09/25
09/25
WRAP, NCT05062291: Merit SODY™ Endoprosthesis for Treatment of Stenosis or Occlusion

Recruiting
N/A
500
Europe, RoW
Merit WRAPSODY Endovascular Stent Graft
Merit Medical Systems, Inc.
Venous Stenosis, Venous Occlusion
12/25
07/27
NCT04907240: Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry

Recruiting
N/A
614
Europe
GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
W.L.Gore & Associates
Peripheral Artery Disease, Popliteal Aneurysm, Hemodialysis Access, Visceral Artery Aneurysms, Trauma Injury
10/26
10/35
Li, Li
NCT06697522: Study of Atropine Sulfate Eye Drops(0.01%) in Treating Near-work-induced Transient Myopia in Children

Completed
3
148
RoW
Atropine Sulfate, Investigational product, Placebo, Blank Solvent
Ocumension Therapeutics (Suzhou) Co., Ltd, Beijing Children's Hospital
Myopia
10/23
03/24
NCT05793892: Efficacy and Safety of Lidocaine and Tetracaine Cream for Facial Laser Aesthetics in Chinese Adults

Completed
3
286
RoW
Lidocaine tetracaine cream, test drug:CU-30101, control drug:Pliaglis
Cutia Therapeutics（Wuxi）Co.,Ltd
Analgesia
08/23
10/23
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
928
Europe, Canada, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Diabetes, Type 2 Diabetes
04/24
04/24
ATTAIN-OSA, NCT06649045: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Recruiting
3
600
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
OSA, Overweight or Obesity
11/26
01/27
NCT06717152: Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease

Recruiting
3
400
RoW
SJP-0132, Placebo
Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd., Senju Pharmaceutical Co., Ltd.
Dry Eye
07/25
08/25
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
3000
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Overweight or Obesity
07/25
07/27
TRIUMPH-1, NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Active, not recruiting
3
2300
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea
04/26
05/26
JSKN003-102, NCT05744427: Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors

Hourglass Dec 2024 - Dec 2024 : Results for HER2-low, U/M BC
Recruiting
1/2
725
RoW
JSKN003
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Solid Tumor
12/24
12/26
OPAL-1, NCT05970497: A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
240
US
KB707, Opdualag, KEYTRUDA ®( Pembrolizumab)
Krystal Biotech, Inc.
Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma
07/27
07/27
TQB2858-Ⅰ-06, NCT05068921: A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy

Recruiting
1
40
RoW
TQB2858 injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Cervical Cancer
05/23
07/23
NCT06678581: SAD,MAD and Food Effect Study of SAP-001 Tablets in Chinese Subjects

Completed
1
70
RoW
SAP-001, SAP-001 tablet, Placebo, placebo tablet
Shanton Pharma Co., Ltd.
Gout, Hyperuricemia
12/23
01/24
DEVIF-I, NCT06230822: Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Recruiting
1
9
RoW
VUM02 Injection, Human Umbilical Cord Tissue-derived Mesenchymal Stem Cells Injection
Wuhan Optics Valley Vcanbiopharma Co., Ltd.
Idiopathic Pulmonary Fibrosis
01/25
12/26
OASIS, NCT06063317: A Study of OnCARlytics (CF33-CD19) in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors

Recruiting
1
33
US
CF33-CD19 IT, CF33-CD19 IV, Blinatumomab, Blincyto
Imugene Limited
Solid Tumor, Adult
06/27
05/29
Thompson, Cheryl
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
Ellis, Rodney
STEEL, NCT03809000: A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

Active, not recruiting
2
188
Canada, US
Radiation Therapy, RT, Image-Guided Radiation Therapy (IGRT), Radiotherapy, Enzalutamide, Xtandi®, Bicalutamide, Casodex®, GnRH analog, Gonadotropin-releasing hormone analog, Lupron®, leuprolide acetate, goserelin acetate, Eligard™, Viadur™, Zoladex®, Trelstar®
RTOG Foundation, Inc., Pfizer, Astellas Pharma Inc
Prostate Cancer
04/23
09/29
SABRE, NCT04905069: Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy

Recruiting
N/A
500
Europe, US, RoW
SpaceOAR Vue System
Boston Scientific Corporation
Prostate Cancer
04/27
04/30
Owusu, Cynthia
NCT05161195 / 2021-005184-42: Roll-over Study to Allow Continued Access to Ribociclib

Recruiting
4
137
Europe, Japan, US, RoW
Ribociclib, Letrozole, Anastrozole, Goserelin, Tamoxifen, Fulvestrant
Novartis Pharmaceuticals, Novartis Pharma AG
Metastatic Breast Cancer
01/28
02/28
Shah, Chirag
NCT05872269: A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities

Recruiting
4
1500
RoW
Saroglitazar
Zydus Lifesciences Limited
NAFLD, Obesity, Type 2 Diabetes, Dyslipidemias, Metabolic Syndrome
01/25
06/25
RheSolve, NCT04677465: Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis

Active, not recruiting
N/A
270
Europe, US
RheOx Bronchial Rheoplasty, Sham Procedure
Gala Therapeutics, Inc.
Chronic Bronchitis
05/24
10/25
CASE5Y21, NCT05142358: A Prospective Study to Evaluate Continuous Positive Airway Pressure Devices to Reduce Pulmonary Dose

Recruiting
N/A
90
US
Continuous Positive Airway Pressure, CPAP, Deep inspiratory breath hold, DIBH, Free Breath, Without DIBH
Case Comprehensive Cancer Center, Varian Medical Systems
Lung Cancer, Left Sided Breast Cancer
06/25
12/25
PREDICT, NCT03448926: The Registry:

Recruiting
N/A
3000
US
Treatment Recommendation Surveys, 7-gene biosignature
PreludeDx, University of South Florida
DCIS
12/25
12/35
Eads, Jennifer
NCT03921021: Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

Completed
2
17
US
Telomelysin, OBP-301
Weill Medical College of Cornell University, Oncolys BioPharma Inc
Esophagogastric Adenocarcinoma
06/23
07/23
NCT05733611: RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Active, not recruiting
2
4
NA
RP2, RP3, atezolizumab, bevacizumab
Replimune Inc., Roche Pharma AG
Refractory Metastatic Colorectal Cancer, pMMR, MSS
01/27
03/27
CHM-2101-001, NCT06055439: A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

Recruiting
1/2
135
US
CHM-2101 CAR-T cells
Chimeric Therapeutics
Neuroendocrine Tumors, Colorectal Cancer, Gastric Cancer
05/26
05/27
NCT03854110: Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine

Recruiting
1
64
US
GP-2250, gemcitabine
Geistlich Pharma AG, Translational Drug Development
Pancreatic Cancer, Adult
09/24
12/24
Caimi, Paolo
ALPHA3, NCT06500273: Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Recruiting
2
250
US
cemacabtagene ansegedleucel, cema-cel, ALLO-647, Fludarabine, Fludara®, Cyclophosphamide, Cytoxan®, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™, Foresight Lymphoma MRD Therapy Selection Test
Allogene Therapeutics, Foresight Diagnostics, Inc.
Large B-cell Lymphoma
08/27
08/31
PRO1160-001, NCT05721222: PRO1160 for Advanced Solid and Liquid Tumors

Recruiting
1/2
134
US, RoW
PRO1160
ProfoundBio US Co.
Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma
11/26
03/27
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Checkmark From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Hourglass Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL
More
Recruiting
1/2
320
Canada, US
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Juno Therapeutics, a Subsidiary of Celgene
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
11/27
11/27
NCT03921879: Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma

Recruiting
1
50
US
OT-82 Dose Escalation, OT-82 Dose Expansion
Oncotartis, Inc.
Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Follicular, Lymphoma, Peripheral T-Cell, Lymphoma, Hodgkin
04/21
06/21
LMY-920-001, NCT05312801: Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

Recruiting
1
20
US
BAFF CAR-T, LMY-920
Luminary Therapeutics, Case Comprehensive Cancer Center
Lymphoma, Non-Hodgkin Lymphoma, B-Cell
05/25
09/25
NCT06447376: Study of Cytokine Release Syndrome Prophylaxis and Treatment with Siltuximab Prior to Epcoritamab

Recruiting
1
20
US
Siltuximab, Epcoritamab
Paolo Caimi, MD, Genmab, AbbVie, Recordati Rare Diseases
Non-Hodgkin Lymphoma, Cytokine Release Syndrome
09/28
09/28
Murphy, Erin S
NCT05409976: The GORE® VIAFORT Vascular Stent IVC Study

Active, not recruiting
N/A
111
Europe, US, RoW
GORE® VIAFORT Vascular Stent
W.L.Gore & Associates
Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
01/25
01/29
NCT05489588: The GORE® VIAFORT Vascular Stent Iliofemoral Study

Active, not recruiting
N/A
165
US
GORE® VIAFORT Vascular Stent
W.L.Gore & Associates
Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
04/25
04/29
Ahluwalia, Manmeet
NCT05317858: Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

Recruiting
3
20
Canada, US, RoW
Blood Brain Barrier Disruption - Oncology, Exablate BBBD, Pembrolizumab
InSightec
Brain Tumor
06/24
12/24
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC).

Completed
3
298
Europe, Canada, US, RoW
NovoTTF-200M device, Best Standard of Care
NovoCure GmbH
Brain Metastases from Non-small Cell Lung Cancer (NSCLC)
11/24
11/24
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting
3
560
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Active, not recruiting
2
247
US
SurVaxM
MimiVax, LLC, Translational Drug Development, Merit
Newly Diagnosed Glioblastoma
08/24
08/24
NCT05188508: Pembrolizumab, Olaparib, and Temozolomide for People with Glioma

Recruiting
2
57
US
Pembrolizumab, Olaparib and Temozolomide
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC
Glioma
01/26
01/26
NCT02575794: Terameprocol in Treating Patients With Recurrent High Grade Glioma

Completed
1
20
US
Terameprocol, 1,1'-(2,3-Dimethyl-1,4-butanediyl)bis(3,4-dimethoxybenzene), EM-1421, M4N, tetra-O-methyl NDGA, Tetra-O-methyl Nordihydroguaiaretic Acid, TMNDGA, Pharmacological Study, Pharnacological Study
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Erimos Pharmaceuticals, National Cancer Institute (NCI)
High Grade Glioma (III or IV)
09/23
10/23
NCT04901806 / 2021-001029-32: Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Terminated
1
29
Europe, US, RoW
PBI-200
Pyramid Biosciences, Pyramid Biosciences, Inc., Pyramid Biosciences
Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor
07/23
07/23
TUTOR, NCT05553522: Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer

Recruiting
1
40
US
Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine
Baptist Health South Florida, Pfizer
Brain Metastases, HER2-positive Breast Cancer
02/28
02/29
LIBERATE, NCT05383872: Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with GlioBlastoma Brain Tumors

Recruiting
N/A
57
Canada, US
Focused Ultrasound (Exablate Model 4000)
InSightec
Glioblastoma, Glioma, Liquid Biopsy
12/24
03/25
NCT05756985: Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue

Recruiting
N/A
120
US
Specimen Collection
Baptist Health South Florida, Miami Cancer Institute, Nico Corporation
Glioblastoma, Glioblastoma Multiforme, Gliosarcoma
01/27
01/29
Hamilton, Betty
Precision-T (PhIII component), NCT05316701: Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active, not recruiting
3
174
US
Orca-T, Standard-of-Care, SOC
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia, Myelodysplastic Syndrome, Acute Leukemia, Therapy-Related Myelodysplastic Syndrome
04/25
04/27
Precision-T, NCT04013685: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active, not recruiting
1
255
US
Orca-T
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Myeloid Leukemia
07/24
07/26
NCT05544032: Expanded Access Program for Axatilimab in Chronic Graft Versus Host Disease (GVHD)

Available
N/A
NA
axatilimab, INCA34176
Incyte Corporation
Chronic Graft Vs. Host Disease
 
 
NCT06649201: Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation

Recruiting
N/A
40
US
Vulvovaginal Symptom Questionnaire, Vaginal Microbiome Evaluation
Case Comprehensive Cancer Center, Incyte Corporation
Graft Vs Host Disease, Vulvovaginal Signs and Symptoms
02/26
02/27
Dorth, Jennifer
GRECO-2, NCT04698915: Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

Terminated
2
177
Europe, Canada, US
Drug GC4711, Placebo
Galera Therapeutics, Inc.
SBRT, Borderline Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer
11/23
11/23
Rogers, Lisa
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
01/26
01/28
Malek, Ehsan
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
NCT02833610: A Study of Denosumab in Multiple Myeloma Patients with Renal Insufficiency

Completed
2
55
US
Denosumab Q4W, Xgeva, Prolia
Massachusetts General Hospital, Amgen, Emory University, University of Rochester, University Hospitals Cleveland Medical Center
Multiple Myeloma
03/23
03/23
Tendulkar, Rahul D
PREDICT, NCT03448926: The Registry:

Recruiting
N/A
3000
US
Treatment Recommendation Surveys, 7-gene biosignature
PreludeDx, University of South Florida
DCIS
12/25
12/35
Chakrabarti, Sakti
REGPEM-CRC-01, NCT06006923: Regorafenib in Combination with Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

Recruiting
2
154
US
Regorafenib, BAY 73-4506, Stivarga, Pembrolizumab, Keytruda
Ibrahim Halil Sahin, Bayer
MSI-H Colorectal Cancer
06/26
06/29
Gallogly, Molly
SER-155-001, NCT04995653: A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

Completed
1
60
US
Vancomycin Pre-Treatment, Vancomycin Placebo, SER-155, SER-155 Placebo
Seres Therapeutics, Inc., Memorial Sloan Kettering Cancer Center
Allogeneic Hematopoietic Stem Cell Transplantation
07/24
07/24
Rao, Santosh
DORA, NCT03574571 / 2018-002944-10: A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Recruiting
3
738
Europe, US, RoW
Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223
Memorial Sloan Kettering Cancer Center, Bayer
Prostate Cancer
06/26
06/26
Lynam, Sarah
UP-NEXT, NCT05329545: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer

Terminated
3
20
Canada, US, RoW
Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo
Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
09/23
09/23
HOTT, NCT05659381: Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Recruiting
3
230
US
Cisplatin, Platinol AQ, No treatment
GOG Foundation, GlaxoSmithKline
Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer
08/29
08/34
NCT05113368: Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
2
31
US
Regorafenib, Fulvestrant
Sarah K. Lynam MD, Bayer
Ovarian Cancer, Serous Ovarian Cancer
06/25
12/25
DENALI, NCT05128825: A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Active, not recruiting
2
102
Europe, US, RoW
ZN-c3, azenosertib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
04/25
10/25
Ocuin, Lee M
No trials found

Download Options